Zogenix

Latest news

• Fintepla (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)
  28 March 2022
• FDA Approves Fintepla (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome
  25 June 2020
• Zogenix Announces FDA Extension of Review Period for Fintepla in Dravet Syndrome
  27 February 2020
• Zogenix Announces Positive Top-line Results from Global Pivotal Phase 3 Trial of Fintepla for the Treatment of Lennox-Gastaut Syndrome
  6 February 2020
• The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug Fintepla in Dravet Syndrome
  17 December 2019
• JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug Fintepla in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens
  2 December 2019
• Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for Fintepla for the Treatment of Dravet Syndrome
  25 November 2019
• Zogenix Resubmits New Drug Application for Fintepla for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration
  26 September 2019
• Zogenix Announces FDA Agreement to Proceed with Resubmission of Fintepla NDA
  27 June 2019
• Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for Fintepla New Drug Application
  8 April 2019

Drugs Associated with Zogenix, Inc.

Zogenix, Inc. manufactures, markets and/or distributes more than 1 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.

Discontinued Drugs